THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION PURSUANT TO ARTICLE 7 OF EU REGULATION 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

8 April 2025

Belluscura plc

("Belluscura" or the "Company")

Statement re proposed imposition of Tariffs

Belluscura plc (AIM: BELL), a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies, notes the proposed imposition of tariffs on imports to the United States of America announced by the US Administration last week.

The Company is currently assessing the potential financial implications, risks and opportunities of the imposition of tariffs, in particular the 54% tariff (previously 20%) for goods imported from China, in which a significant proportion of the Company's Portable Oxygen Concentrators, raw materials and component parts are currently manufactured. 

In the light of the above, the Company withdraws its previous market guidance for the current year ending 31 December 2025 (as referred to in its notification of 6 February 2025).

The Company expects to make a further announcement once it has been able to better assess the situation, including possible subsequent developments.

For further information please contact:

For further information, please visit https://ir.belluscura.com/